Bayer CEO launches ‘full-scale effort’ to rejuvenate pharma pipeline, tables split-up but warns not never

Bill Anderson, nine months into Bayer’s CEO role, has laid out his priorities for the troubled German conglomerate in the next few years—and it doesn’t involve an immediate business split-up as many investors had hoped for.